Skip to content
Search

Latest Stories

Predictive value of 'good' cholesterol level varies by race, U.S. study finds

The widely-held concept that levels of good cholesterol in the blood can indicate heart disease risk is not equally true for Blacks and whites, and the measure itself may be of less value than previously thought, according to a U.S. study published on Monday (November 21).

Various types of cholesterol are thought to have either healthy or unhealthy effects.


Low levels of so-called "good" high-density lipoprotein (HDL) cholesterol were linked with higher odds for developing cardiac problems in the long-term study - but only in white participants, the study published in the Journal of the American College of Cardiology found.

In contradiction to what has generally been assumed, low HDL levels did not confer any higher risk of heart disease in Black people, researchers said. Among white people, however, those with HDL levels below 40 milligrams per deciliter had a 22% higher risk for coronary heart disease compared with those whose HDL levels were higher.

High HDL levels (above 60 mg/dL), which are thought to be protective, were not linked with lower coronary heart disease risks in either race, researchers found.

"Typically at the doctor's office, those of us with higher HDL levels get a pat on the back" for being at lower risk, said study leader Nathalie Pamir of Oregon Health & Science University in Portland. "Now, instead of giving a pat on the back to people with high HDL, doctors should do nothing, or say, 'We don't know what this means.'"

High levels of "bad" low-density lipoprotein (LDL) cholesterol, typically treated with widely-used statins such as Lipitor, and triglycerides were associated with increased heart disease risks in both races, her team found.

The study, funded by the National Institutes of Health, collected data over roughly 10 years from nearly 24,000 U.S. adults, about 42% of whom were Black. Participants of both races were similar in age, cholesterol levels, and other heart disease risk factors, the researchers said.

The early studies that shaped perceptions about healthy cholesterol levels overwhelmingly involved white American participants, Pamir said. "Our study puts a big question mark on the available biomarkers that we use to assess risk because they were developed without having all races in mind."

Dr. Keith Ferdinand of Tulane University in New Orleans, who was not involved in the research, warned in an editorial that using HDL cholesterol levels to estimate risk "could inaccurately assess and possibly misclassify (coronary artery disease) risk in Black adults and become a barrier to optimal care."

Better estimates might be obtained, Ferdinand wrote, by measuring the amount of calcium that has accumulated in patients' arteries and monitoring their levels of a form of cholesterol called Lp(a).

In all cases, he added, regardless of biomarker levels, "therapeutic lifestyle changes are the bedrock of prevention."

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Pharmacy First: Government confirms £215 million boost to realise its full potential

From April 2025, the consultation fee for Pharmacy First Minor Illness and Clinical Pathways will rise from £15 to £17.

‘Pharmacy First hasn't realised its full potential,’ says Stephen Kinnock

Health Minister Stephen Kinnock has acknowledged that Pharmacy First has huge potential, noting that the service “hasn't realised its full potential.”

As part of efforts to enhance the service, Kinnock yesterday (30) announced £215 million in additional funding for Pharmacy First and other Primary Care Access Recovery Plan services.

Keep ReadingShow less
New CPCF funding: “This is the best deal community pharmacy has had in a decade”

This new funding settlement marks a significant step forward in addressing the long term underinvestment in community pharmacy, says RPS England chair Tase Oputu

Pharmacy bodies hail new funding settlement as ‘best deal for community pharmacy in a decade’

Pharmacy bodies have welcomed the new funding settlement for community pharmacies, highlighting its potential to enhance patient access to care and medicines while addressing a decade of underinvestment in the sector.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a record £3.073 billion funding package for 2025/26, along with an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less